Beam Therapeutics vs 4D Molecular Therapeutics
BEAM and FDMT side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BEAM and FDMT compare
Beam Therapeutics is the larger company, worth 2.8 times as much as 4D Molecular Therapeutics ($2.7B against $938M).
4D Molecular Therapeutics grew revenue faster over the last twelve months (278712% versus 159% for Beam Therapeutics).
Beam Therapeutics keeps more of each dollar of sales as profit, with a net margin of −54.7% compared with −195% at 4D Molecular Therapeutics.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BEAM | FDMT |
|---|---|---|
| Size and price | ||
| Market cap | $2.7B | $938M |
| Share price | $25.81 | $12.99 |
| Change, 1 year | 19.2% | 27.7% |
| Change, 5 years | −71.2% | −43.7% |
| Beta (5Y) | 2.01 | 1.35 |
| Employees | 511 | 196 |
| StockData Score | ||
| Total score | 7 | 7 |
| Valuation score | 0 | 0 |
| Growth score | 2 | 2 |
| Performance score | 2 | 2 |
| Health score | 3 | 3 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 17.1× | 10.2× (better) |
| P/B | 2.5× | 2.3× (better) |
| FCF yield | −14.0% | – |
| Fair value | $24.42 | $12.76 |
| Margin of safety | −5.7% | −1.8% (better) |
| Growth | ||
| Revenue growth (TTM) | 159% | 278712% (better) |
| Revenue growth, 5Y average | 466% (better) | 44.3% |
| Profitability | ||
| Operating margin | −242% | −214% (better) |
| Net margin | −54.7% (better) | −195% |
| FCF margin | −239% | – |
| Return on equity | −8.1% (better) | −43.3% |
| Return on invested capital | – | −161% |
| Financial health | ||
| Debt / equity | 0.09 | 0.05 (better) |
| Current ratio | 14.57 (better) | 8.03 |
| Altman Z-score | 3.30 | 3.87 (better) |
| Piotroski F-score | 4 | 4 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 106% | 80.5% |
| Held by insiders | 3.4% | 2.1% |
| Insider net buying, 12 months | −$19.7M | −$5.3M (better) |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 26.1% | 15.4% |
Go deeper
- BEAM stock overview
- BEAM income statement
- BEAM valuation and score
- FDMT stock overview
- FDMT income statement
- FDMT valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.